Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands

被引：25

作者：

Rogoza, R. M. ^{[1
]}

Westra, T. A. ^{[2
,3
]}

Ferko, N. ^{[1
]}

Tamminga, J. J. ^{[4
]}

Drummond, M. F. ^{[5
,6
]}

Daemen, T. ^{[2
]}

Wilschut, J. C. ^{[2
]}

Postma, M. J. ^{[3
,7
]}

机构：

[1] i3 Innovus, Hlth Econ & Outcomes Res, Burlington, ON, Canada

[2] Univ Med Ctr Groningen, Dept Med Microbiol, Mol Virol Sect, NL-9700 RB Groningen, Netherlands

[3] Univ Groningen, Dept Pharm, Unit Pharmacoepidemiol & Pharmacoecon, Groningen, Netherlands

[4] GlaxoSmithKline, Hlth Outcomes, Zeist, Netherlands

[5] i3 Innovus, Uxbridge, Middx, England

[6] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England

[7] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands

来源：

VACCINE | 2009年 / 27卷 / 35期

关键词：

HPV; Cost-effectiveness; Cervical cancer; The Netherlands; PARTICLE VACCINE; HIGH-RISK; SUSTAINED EFFICACY; ECONOMIC-IMPACT; YOUNG-WOMEN; INFECTION; TYPE-16; HEALTH; SMEARS; STRATEGIES;

D O I：

10.1016/j.vaccine.2009.05.085

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cervical cancer is one of the most prevalent cancers among women worldwide. Implementation of an HPV-vaccination strategy targeting the major oncogenic types 16 and 18 that cause cervical cancer is generally expected to significantly reduce the burden of cervical cancer disease. Here we estimate the costs, savings and health gains with the addition of HPV-16/18 vaccination to the already existing Dutch screening programme. In the base-case analysis, it was estimated that implementation of an HPV-16/18 vaccine would result in an incremental cost-effectiveness ratio (ICER) of (sic)22,700 per life-year gained (LYG). In sensitivity analysis, the robustness of our finding of favourable cost-effectiveness was established. The ICER appeared sensitive to the vaccine price, discount rate and duration of vaccine-induced protection. From our results, it validly follows that immunization of 12-year-old Dutch girls against HPV-16/18 infection is a cost-effective strategy for protecting against cervical cancer. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：4776 / 4783

页数：8

共 70 条

[1]

[Anonymous], 2001, MACROECONOMICS HLTH

[2] Review of current knowledge on HPV vaccination: An Appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening [J].

Arbyn, Marc ;

Dillner, Joakim .

JOURNAL OF CLINICAL VIROLOGY, 2007, 38 (03) :189-197

[3] The epidemiology of human papillomavirus infections [J].

Baseman, JG ;

Koutsky, LA .

JOURNAL OF CLINICAL VIROLOGY, 2005, 32 :S16-S24

[4]

Berkers L M, 2007, Ned Tijdschr Geneeskd, V151, P1288

[5] Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis [J].

Berkhof, J ;

de Bruijne, MC ;

Zielinski, GD ;

Bulkmans, NWJ ;

Rozendaal, L ;

Snijders, PJF ;

Verheijen, RHM ;

Meijer, CJLM .

INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (07) :1759-1768

[6] Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands [J].

Berkhof, J ;

de Bruijne, MC ;

Zielinski, GD ;

Meijer, CJLM .

INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (02) :268-275

[7] Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands [J].

Boot, Hein J. ;

Wallenburg, Iris ;

de Melker, Hester E. ;

Mangen, Marie-Jose M. ;

Gerritsen, Annette A. M. ;

van der Maas, Nicoline A. ;

Berkhof, Johannes ;

Meijer, Chris J. L. M. ;

Kimman, Tieerd G. .

VACCINE, 2007, 25 (33) :6245-6256

[8]

Bos A B, 2002, Ned Tijdschr Geneeskd, V146, P1586

[9] The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada [J].

Brisson, Marc ;

Van de Velde, Nicolas ;

De Wals, Philippe ;

Boily, Marie-Claude .

VACCINE, 2007, 25 (29) :5399-5408

[10]

Brouwer W, 1998, BRIT MED J, V317, P1155

← 1 2 3 4 5 6 7 →